WAUWATOSA, Wis.--(BUSINESS WIRE)--An abstract of a first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of the isosmolar contrast media (CM) iodixanol and the low-osmolar CM iopromide in patients with chronic kidney disease (CKD) undergoing coronary angiography with or without percutaneous coronary intervention (PCI), was available at this week’s ACC Exposition at McCormick Place.
